Full Text View
Tabular View
No Study Results Posted
Related Studies
ARQ 501 in Combination With Gemcitabine in Subjects With Pancreatic Cancer
This study has been completed.
Study NCT00102700   Information provided by ArQule

First Received on February 1, 2005.   Last Updated on April 28, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Pancreatic Cancer
Adenocarcinoma
Additional conditions recognized in this trial
Adenocarcinoma, Mucinous
Pancreatic Neoplasms
More general conditions related to this trial
Carcinoma
Digestive System Diseases
Digestive System Neoplasms
Endocrine Gland Neoplasms
Endocrine System Diseases
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Cystic, Mucinous, and Serous
Neoplasms, Glandular and Epithelial
Pancreatic Diseases
Additional drug interventions recognized in this trial
Beta-lapachone
Gemcitabine
More general drug interventions related to this trial
Anti-Infective Agents
Anti-Retroviral Agents
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antiviral Agents
Enzyme Inhibitors
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Nucleic Acid Synthesis Inhibitors
Pharmacologic Actions
Physiological Effects of Drugs
Radiation-Sensitizing Agents
Reverse Transcriptase Inhibitors
Therapeutic Uses
Sponsors listed in this trial
ArQule


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services